Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Gilead GILD

Sälj
 Köp

Gilead realtidsdiagram

5m 15m 30m 1h 4h 1d 1w

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Frances Wang 2024 Dec 23, 16:00

SPOT stock price: Spotify stock reaches all-time highs

Stocks
Frances Wang 2024 Dec 23, 16:00

DRCT stock price today: Direct Digital Holdings spikes on high-volume move

Stocks
Frances Wang 2024 Dec 23, 16:00

Stock Market Today: Dow Jones Closes Higher for Third Consecutive Day

Stocks
GDP data
Dyogenes Diniz 2024 Dec 22, 17:00

Morning Note: GDP in the UK, Spain and Canada to Shake Markets Today

Frances Wang 2024 Dec 22, 16:00

Bitcoin ETFs Experience Record Outflows Amid Crypto Market Decline

Cryptocurrencies ETFs
Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies

Info

Spread

0.58

Spread (%)

0.6196 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Torsdag

14:31 - 20:59

Måndag

14:31-20:59

Tisdag

14:31-17:59

Fredag

14:31-20:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

116401618944

Utelöpande aktier

1246269952

Rapportdatum (nästa)

2013-01-28

Utd-procent

2024-12-30

Datum efter utdelning

2024-12-13

Förväntad framtida årlig utdelningsprocent

3.08

Förväntad framtida årlig direktavkastning

0.0333

Vinst per aktie

0.09

Läs mer om detta instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)

Handla nu

Handla nu

Handla nu

Handla nu
Relaterade instrument
Trustpilot
Live Chat